NT-I7 (Efineptakin Alfa) in Combination With Pembrolizumab in Participants With Advanced Solid Tumors
NeoImmuneTech
NeoImmuneTech
AstraZeneca
National Cancer Institute (NCI)
Incyte Corporation
NRG Oncology
National Cancer Institute (NCI)
Sellas Life Sciences Group
Exelixis
Incyte Corporation
Ipsen
Gilead Sciences
Incyte Corporation
Institut Bergonié
Advanced Accelerator Applications
PharmaMar
Pfizer
Amgen
Millennium Pharmaceuticals, Inc.
INSYS Therapeutics Inc